MCLA-129

MCLA-129 is a bispecific antibody developed by Betta Pharmaceuticals and Merus. Its targets are EGFR and MET (the sponsor names EGFR x c-Met). The sponsor states: A human bispecific antibody targeting both EGFR and c-Met, simultaneously blocking the signalling pathways of both receptors to inhibit tumour growth and survival. ClinicalTrials.gov describes the intervention as: MCLA-129 is a bispecific antibody that targets both EGFR and c-Met, simultaneously blocking the signaling pathways of both EGFR and c-Met, thereby inhibiting tumour growth and survival. It is the investigational product in 3 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, in non-small-cell lung cancer, head and neck squamous cell carcinoma, colorectal cancer, gastric & gastro-oesophageal junction cancer and oesophageal cancer. The largest, NCT04930432, plans to enrol 400 participants with primary completion expected 2028-04-30. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.